Recent HIV/AIDS News from HHS and NIAID

From HHS: October 21, 2015: HHS Awards $2.2 Billion in Grants for HIV/AIDS Care and Medications From NIAID: October 21, 2015: Immune Responses Provide Clues for HIV Vaccine Development October 20, 2015: HIV Cure Research: NIH Scientists Create Two-Headed Protein to Deplete HIV Reservoir

Related Links:

This study demonstrates the need to develop and disseminate educational programs for dental providers so they can assist with efforts to raise HPV vaccination rates. PMID: 31690468 [PubMed - as supplied by publisher]
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research
Abstract Acquired Immunodeficiency Syndrome (AIDS), caused by Human Immunodeficiency virus (HIV), is a life-threatening disorder that persists worldwide as a severe health problem. Since it was connected with HIV attachment process, the Chemokine receptor CCR5 has been at the development leading edge of several gene-based therapies. Given the shortcomings of the current anti-retroviral treatment procedure and the non-availability of a licensed vaccine, the aptitude to modify complex genomes with Designer Nucleases has had a noteworthy impact on biotechnology. Over the last years, ZFN, TALEN and CRISPR/Cas9 gene-ed...
Source: Current HIV Research - Category: Infectious Diseases Authors: Tags: Curr HIV Res Source Type: research
A 25 year-old tuberculosis patient is treated at her home in Funafuti, the main island of Tuvalu in the South Pacific. Credit: UNDP Tuvalu/Aurélia Rusek.By External SourceUNITED NATIONS, Oct 17 2019 (IPS) A staggering 1.5 million people died from tuberculosis (TB) last year, the UN health agency said on Thursday, in an appeal for far greater funding and political support to eradicate the curable and preventable disease. Caused by the bacteria Mycobacterium tuberculosis, TB commonly causes persistent coughing, fatigue and weight loss. According to the World Health Organization (WHO) and its latest Global TB Report, a...
Source: IPS Inter Press Service - Health - Category: International Medicine & Public Health Authors: Tags: Global Headlines Health Poverty & SDGs Source Type: news
Publication date: December 2019Source: Microbial Pathogenesis, Volume 137Author(s): Faruq Abdulla, Utpal Kumar Adhikari, M. Kamal UddinAbstractTill now, AIDS, caused by the human immunodeficiency virus (HIV) is still a severe health problem worldwide. It weakens the immune system by targeting the T-helper cells. Specifically, the severity of the pandemic HIV-1 makes the emergence of an enduring effective vaccine against HIV-1. Therefore, we have applied a series of immunoinformatics approaches to the four conserved domains of HIV-1 integrase (IN) proteins to design an effective multi-epitope based subunit vaccine which mig...
Source: Microbial Pathogenesis - Category: Infectious Diseases Source Type: research
Condition:   HIV-1-infection Interventions:   Biological: Vaccine and vedolizumab (Entyvio);   Biological: Placebo vaccine and vedolizumab infusion (Entyvio);   Biological: Placebo vaccine and placebo infusion Sponsors:   French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS);   EuroVacc Foundation;   European AIDS Treatment Group (EATG);   Medical Research Council;   University College London, UK.;  ...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   HIV-1-infection Interventions:   Biological: Vaccine and vedolizumab (Entyvio);   Biological: Placebo vaccine and vedolizumab infusion (Entyvio);   Biological: Placebo vaccine and placebo infusion Sponsors:   French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS);   EuroVacc Foundation;   European AIDS Treatment Group (EATG);   Medical Research Council;   University College London, UK.;  ...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   HIV-1-infection Interventions:   Biological: Vaccine and vedolizumab (Entyvio);   Biological: Placebo vaccine and vedolizumab infusion (Entyvio);   Biological: Placebo vaccine and placebo infusion Sponsors:   French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS);   EuroVacc Foundation;   European AIDS Treatment Group (EATG);   Medical Research Council;   University College London, UK.;  ...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   HIV-1-infection Interventions:   Biological: Vaccine and vedolizumab (Entyvio);   Biological: Placebo vaccine and vedolizumab infusion (Entyvio);   Biological: Placebo vaccine and placebo infusion Sponsors:   French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS);   EuroVacc Foundation;   European AIDS Treatment Group (EATG);   Medical Research Council;   University College London, UK.;  ...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   HIV-1-infection Interventions:   Biological: Vaccine and vedolizumab (Entyvio);   Biological: Placebo vaccine and vedolizumab infusion (Entyvio);   Biological: Placebo vaccine and placebo infusion Sponsors:   French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS);   EuroVacc Foundation;   European AIDS Treatment Group (EATG);   Medical Research Council;   University College London, UK.;  ...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Background: Very limited data are available on the immunovirological outcomes after 13-valent pneumococcal conjugate vaccine (PCV13) in antiretroviral therapy (ART)-treated patients. The aim of this study was to assess the immune-virological outcomes in HIV-1-infected ART-treated patients on stable virological suppression who underwent pneumococcal conjugate vaccination. Methods: Retrospective, cohort study on ART-treated HIV-1-infected individuals, age at least 18 years, with three consecutive determinations of HIV-RNA less than 50 copies/ml before the administration of PCV13 (baseline) at San Raffaele Hospital and w...
Source: AIDS - Category: Infectious Diseases Tags: CLINICAL SCIENCE Source Type: research
More News: AIDS Vaccine | Department of Health | Grants | Health | HIV AIDS | Infectious Diseases | Vaccines